Understanding exactly how amyloid proteins fold and stack into the plaques that characterize Alzheimer's disease has been a decades-long bottleneck in drug development. A precise atomic blueprint of the most common fibril form could finally give medicinal chemists a reliable molecular lock to design keys against — potentially explaining why so many anti-amyloid therapies have failed or shown only partial efficacy.
Published in PNAS, this structural biology study resolves the three-dimensional architecture of monomorphic Aβ1-40 fibrils at high resolution using advanced cryo-electron microscopy or solid-state NMR techniques. The term "monomorphic" is significant: it means the fibrils adopt a single, reproducible conformation rather than the heterogeneous polymorphic forms that have historically plagued structural studies. The Aβ1-40 alloform — the shorter of the two dominant amyloid-beta variants — is the more abundant species in the brain, though its longer counterpart Aβ1-42 has traditionally received more research attention due to its greater aggregation propensity and toxicity. This new structural map reveals the precise intermolecular contacts, β-sheet geometry, and hydrophobic core arrangements that stabilize the fibril, offering distinct binding pockets not previously characterized at this resolution.
This finding sits within a rapidly maturing field: since cryo-EM resolution improved dramatically post-2017, several Aβ1-42 and tau fibril structures have been mapped, but Aβ1-40 structural data has lagged. The monomorphic nature of these fibrils is a meaningful scientific asset — polymorphic samples produce averaged or ambiguous density maps, so a single dominant conformation yields far more actionable structural data. The practical caveat is considerable, however: in vivo, both Aβ alloforms coexist in mixed and patient-derived polymorphic states, meaning this idealized structure may not perfectly represent plaque architecture in living brains. This is foundational, confirmatory-plus work — incremental in isolation but potentially paradigm-shifting if it enables structure-based drug design targeting Aβ1-40 specifically, a route largely unexplored compared to Aβ1-42-centric approaches.